Table 1.
Prevalence of immune cell types in sentinel vs. non-sentinel nodes and in positive vs. negative SLNs
|
Study (reference) |
Tumor |
Number of |
Number of |
Dendritic cells |
Mature DCs |
Plasmacytoid DCs |
T cells |
Regulatory T cells |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| type | patients (SLNs) | + / - SLNs | SLN vs. NSLN | + vs. - SLN | SLN vs. NSLN | + vs. - SLN | SLN vs. NSLN | + vs. - SLN | SLN vs. NSLN | + vs. - SLN | SLN vs. NSLN | + vs. - SLN | |
|
Compared to NSLNs of the same patient cohort |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cochran et al. 2001 [3] |
melanoma |
11 (21) |
10 / 11 |
lower |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
| Botella-Estrada et al. 2005 [4] |
melanoma |
10 (17) |
1 / 16 |
higher |
NT |
no diff. |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
| Gerlini et al. 2007 [20] |
melanoma |
27 (39) |
8 / 31 |
NT |
NT |
NT |
NT |
NT |
higher |
NT |
NT |
NT |
NT |
| Speeckaert et al. 2011 [14] |
melanoma |
116 (116) |
26 / 90 |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
higher |
| Ma et al. 2012 [15] |
melanoma |
84 (84) |
31 / 53 |
NT |
lower |
NT |
higher |
NT |
NT |
NT |
NT |
NT |
higher |
| Huang et al. 2000 [2]2 |
breast cc. |
21 (21) |
not spec. |
lower |
NT |
lower |
NT |
NT |
NT |
lower |
NT |
NT |
NT |
| Kohrt et al. 2005 [7]2 |
breast cc. |
29 (29) |
29 / 0 |
lower |
NT |
NT |
NT |
NT |
NT |
lower (CD4+) |
NT |
NT |
NT |
| Bembenek et al. 2008 [6] |
breast cc. |
79 (114) |
51 / 283 |
NT |
NT |
higher |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
| Ishigami et al. 2003 [11] |
gastric cc. |
27 (27) |
8 / 19 |
no diff. |
no diff. |
NT |
NT |
NT |
NT |
no diff. |
no diff. |
NT |
NT |
| Lee et al. 2011 [13] |
gastric cc. |
64 (64) |
45 / 193 |
NT |
NT |
NT |
no diff. |
NT |
NT |
NT |
no diff. |
NT |
higher |
| Sakakura et al. 2005 [5] |
oral cc. |
12 (41) |
0 / 41 |
higher |
NT |
no diff. |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
|
Compared to non-tumor control nodes |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mansfield et al. 2011 [10] |
melanoma |
20 (20) |
8 / 12 |
NT |
NT |
lower |
no diff. |
no diff. |
no diff. |
lower (CD8+) |
no diff. |
no diff. |
no diff. |
| Poindexter et al. 2004 [12] |
breast cc. |
50 (50) |
25 / 25 |
no diff. |
no diff. |
no diff. |
lower |
NT |
NT |
NT |
NT |
NT |
NT |
| Mansfield et al. 2009, 2011 [8,9] | breast cc. | 47 (47) | 36 / 11 | no diff. | no diff. | higher | lower | no diff. | no diff. | higher (CD8+) | no diff. | no diff. | higher |
Columns SLN vs. NSLN: comparison of negative SLNs to negative NSLNs or controls (except in studies [2] and [7]); columns + vs. - SLN: comparison of positive to negative SLNs.
1SLNs and NSLNs of unspecified status were compared; 2positive SLNs were compared to mixed (+ and -) NSLNs; also compared to non-tumor controls, with similar results
3number of patients with + / - SLN status; NT: not tested;no diff.: no difference; not spec.: not specified.